Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

Inclusion Criteria

• •To be eligible to participate in this trial, a patient must:
• •Have a diagnosis of SLE according to 4 of the American College of Rheumatology revised criteria
• •Have active SLE
• •Have moderate to severe rash and/or arthritis as demonstrated by BILAG-2004 score A or B in the mucocutaneous and/or musculoskeletal body systems at both Screening and Randomization Visits
• •Have a documented history or screening result of
• •1. positive antinuclear antibody (ANA), OR
• •2. elevated anti-dsDNA or extractable nuclear antigen (ENA) antibodies
• •Have been on prednisone (or prednisone equivalent) before the screening visit:
• •1. at least 8 weeks, and
• •2. at a stable dose of 7.5 mg to 30 mg for at least 4 weeks